Switch theme
Sign up to access all valuation multiples
AFT Pharmaceuticals Ltd is a pharmaceutical distributor and developer of pharmaceutical intellectual property. Some of the products of the organization are Aqueous cream, Calci-tab, Maxigesic, Cromo-fresh, Crystaderm, Crytawash, Ellgy plus, Emulsifying ointment, and others. The group has four operating segments based on geographical location being, Australia, New Zealand, Asia, and the Rest of the world. It generates the majority of the revenue from Australia which includes the sales and distribution activity relating to the Australian market.
1997
110
LTM Revenue $128M
LTM EBITDA $12.7M
$189M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
AFT Pharmaceuticals has a last 12-month revenue (LTM) of $128M and a last 12-month EBITDA of $12.7M.
In the most recent fiscal year, AFT Pharmaceuticals achieved revenue of $122M and an EBITDA of $12.8M.
AFT Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See AFT Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $128M | XXX | $122M | XXX | XXX | XXX |
| Gross Profit | $56.3M | XXX | $53.1M | XXX | XXX | XXX |
| Gross Margin | 44% | XXX | 43% | XXX | XXX | XXX |
| EBITDA | $12.7M | XXX | $12.8M | XXX | XXX | XXX |
| EBITDA Margin | 10% | XXX | 10% | XXX | XXX | XXX |
| EBIT | $11.2M | XXX | $7.0M | XXX | XXX | XXX |
| EBIT Margin | 9% | XXX | 6% | XXX | XXX | XXX |
| Net Profit | $7.5M | XXX | $7.1M | XXX | XXX | XXX |
| Net Margin | 6% | XXX | 6% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $9.3M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, AFT Pharmaceuticals's stock price is NZD 3 (or $2).
AFT Pharmaceuticals has current market cap of NZD 299M (or $178M), and EV of NZD 318M (or $189M).
See AFT Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $189M | $178M | XXX | XXX | XXX | XXX | $0.07 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, AFT Pharmaceuticals has market cap of $178M and EV of $189M.
AFT Pharmaceuticals's trades at 1.6x EV/Revenue multiple, and 13.8x EV/EBITDA.
Equity research analysts estimate AFT Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
AFT Pharmaceuticals has a P/E ratio of 23.6x.
See valuation multiples for AFT Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $178M | XXX | $178M | XXX | XXX | XXX |
| EV (current) | $189M | XXX | $189M | XXX | XXX | XXX |
| EV/Revenue | 1.5x | XXX | 1.6x | XXX | XXX | XXX |
| EV/EBITDA | 14.9x | XXX | 13.8x | XXX | XXX | XXX |
| EV/EBIT | 17.0x | XXX | 22.9x | XXX | XXX | XXX |
| EV/Gross Profit | 3.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | 23.6x | XXX | 23.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 33.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAFT Pharmaceuticals's last 12 month revenue growth is 17%
AFT Pharmaceuticals's revenue per employee in the last FY averaged $1.1M, while opex per employee averaged $0.4M for the same period.
AFT Pharmaceuticals's rule of 40 is 29% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
AFT Pharmaceuticals's rule of X is 54% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for AFT Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 17% | XXX | 16% | XXX | XXX | XXX |
| EBITDA Margin | 10% | XXX | 11% | XXX | XXX | XXX |
| EBITDA Growth | 31% | XXX | 17% | XXX | XXX | XXX |
| Rule of 40 | 29% | XXX | 29% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 54% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 25% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 6% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 38% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
AFT Pharmaceuticals acquired XXX companies to date.
Last acquisition by AFT Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . AFT Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was AFT Pharmaceuticals founded? | AFT Pharmaceuticals was founded in 1997. |
| Where is AFT Pharmaceuticals headquartered? | AFT Pharmaceuticals is headquartered in New Zealand. |
| How many employees does AFT Pharmaceuticals have? | As of today, AFT Pharmaceuticals has 110 employees. |
| Is AFT Pharmaceuticals publicy listed? | Yes, AFT Pharmaceuticals is a public company listed on NZE. |
| What is the stock symbol of AFT Pharmaceuticals? | AFT Pharmaceuticals trades under AFT ticker. |
| When did AFT Pharmaceuticals go public? | AFT Pharmaceuticals went public in 2015. |
| Who are competitors of AFT Pharmaceuticals? | Similar companies to AFT Pharmaceuticals include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of AFT Pharmaceuticals? | AFT Pharmaceuticals's current market cap is $178M |
| What is the current revenue of AFT Pharmaceuticals? | AFT Pharmaceuticals's last 12 months revenue is $128M. |
| What is the current revenue growth of AFT Pharmaceuticals? | AFT Pharmaceuticals revenue growth (NTM/LTM) is 17%. |
| What is the current EV/Revenue multiple of AFT Pharmaceuticals? | Current revenue multiple of AFT Pharmaceuticals is 1.5x. |
| Is AFT Pharmaceuticals profitable? | Yes, AFT Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of AFT Pharmaceuticals? | AFT Pharmaceuticals's last 12 months EBITDA is $12.7M. |
| What is AFT Pharmaceuticals's EBITDA margin? | AFT Pharmaceuticals's last 12 months EBITDA margin is 10%. |
| What is the current EV/EBITDA multiple of AFT Pharmaceuticals? | Current EBITDA multiple of AFT Pharmaceuticals is 14.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
